OBJECTIVES: Beneficial microbes and probiotics are promising agents for the prevention and treatment of enteric and diarrheal diseases in children; however, little is known about their in vivo mechanisms of action. We used a neonatal mouse model of rotavirus diarrhea to gain insight into how probiotics ameliorate acute gastroenteritis. METHODS: Rotavirus-infected mice were treated with 1 of 2 strains of human-derived Lactobacillus reuteri. We assessed intestinal microbiome composition with 16S metagenomic sequencing, enterocyte migration and proliferation with 5-bromo-2'-deoxyuridine, and antibody and cytokine concentrations with multiplex analyses of intestinal explant cultures. RESULTS: Probiotics reduced diarrhea duration, improved intestinal histopathology, and enhanced intestinal microbiome richness and phylogenetic diversity. The magnitude of reduction of diarrhea by probiotics was strain specific and influenced by nutritional status. L reuteri DSM 17938 reduced diarrhea duration by 0, 1, and 2 days in underweight, normal weight, and overweight pups, respectively. The magnitude of reduction of diarrhea duration correlated with increased enterocyte proliferation and migration. Strain ATCC PTA 6475 reduced diarrhea duration by 1 day in all of the mice without increasing enterocyte proliferation. Both probiotic strains decreased concentrations of proinflammatory cytokines, including macrophage inflammatory protein-1α and interleukin-1β, in all of the animals, and increased rotavirus-specific antibodies in all but the underweight animals. Body weight also influenced the host response to rotavirus, in terms of diarrhea duration, enterocyte turnover, and antibody production. CONCLUSIONS: These data suggest that probiotic enhancement of enterocyte proliferation, villus repopulation, and virus-specific antibodies may contribute to diarrhea resolution, and that nutritional status influences the host response to both beneficial microbes and pathogens.
OBJECTIVES: Beneficial microbes and probiotics are promising agents for the prevention and treatment of enteric and diarrheal diseases in children; however, little is known about their in vivo mechanisms of action. We used a neonatal mouse model of rotavirus diarrhea to gain insight into how probiotics ameliorate acute gastroenteritis. METHODS:Rotavirus-infectedmice were treated with 1 of 2 strains of human-derived Lactobacillus reuteri. We assessed intestinal microbiome composition with 16S metagenomic sequencing, enterocyte migration and proliferation with 5-bromo-2'-deoxyuridine, and antibody and cytokine concentrations with multiplex analyses of intestinal explant cultures. RESULTS: Probiotics reduced diarrhea duration, improved intestinal histopathology, and enhanced intestinal microbiome richness and phylogenetic diversity. The magnitude of reduction of diarrhea by probiotics was strain specific and influenced by nutritional status. L reuteri DSM 17938 reduced diarrhea duration by 0, 1, and 2 days in underweight, normal weight, and overweight pups, respectively. The magnitude of reduction of diarrhea duration correlated with increased enterocyte proliferation and migration. Strain ATCC PTA 6475 reduced diarrhea duration by 1 day in all of the mice without increasing enterocyte proliferation. Both probiotic strains decreased concentrations of proinflammatory cytokines, including macrophage inflammatory protein-1α and interleukin-1β, in all of the animals, and increased rotavirus-specific antibodies in all but the underweight animals. Body weight also influenced the host response to rotavirus, in terms of diarrhea duration, enterocyte turnover, and antibody production. CONCLUSIONS: These data suggest that probiotic enhancement of enterocyte proliferation, villus repopulation, and virus-specific antibodies may contribute to diarrhea resolution, and that nutritional status influences the host response to both beneficial microbes and pathogens.
Authors: Eduardo Salazar-Lindo; Stephen Allen; David R Brewster; Elizabeth J Elliott; Alessio Fasano; Alan D Phillips; Ian R Sanderson; Phillip I Tarr Journal: J Pediatr Gastroenterol Nutr Date: 2004-06 Impact factor: 2.839
Authors: Vibeke Rosenfeldt; Kim Fleischer Michaelsen; Mogens Jakobsen; Charlotte Nexmann Larsen; Peter Lange Møller; Pernille Pedersen; Michael Tvede; Heike Weyrehter; Niels Henrik Valerius; Anders Paerregaard Journal: Pediatr Infect Dis J Date: 2002-05 Impact factor: 2.129
Authors: Jos A Boshuizen; Johan H J Reimerink; Anita M Korteland-van Male; Vanessa J J van Ham; Marion P G Koopmans; Hans A Büller; Jan Dekker; Alexandra W C Einerhand Journal: J Virol Date: 2003-12 Impact factor: 5.103
Authors: Elizabeth A Maier; Kristina J Weage; Marjorie M Guedes; Lee A Denson; Monica M McNeal; David I Bernstein; Sean R Moore Journal: Vaccine Date: 2013-11-06 Impact factor: 3.641
Authors: Geoffrey A Preidis; Nadim J Ajami; Matthew C Wong; Brooke C Bessard; Margaret E Conner; Joseph F Petrosino Journal: J Nutr Date: 2016-04-06 Impact factor: 4.798
Authors: Hanne Jensen; Stefan Roos; Hans Jonsson; Ida Rud; Stine Grimmer; Jan-Peter van Pijkeren; Robert A Britton; Lars Axelsson Journal: Microbiology (Reading) Date: 2014-01-28 Impact factor: 2.777
Authors: Bernard J Varian; Theofilos Poutahidis; Brett T DiBenedictis; Tatiana Levkovich; Yassin Ibrahim; Eliska Didyk; Lana Shikhman; Harry K Cheung; Alexandros Hardas; Catherine E Ricciardi; Kumaran Kolandaivelu; Alexa H Veenema; Eric J Alm; Susan E Erdman Journal: Brain Behav Immun Date: 2016-11-05 Impact factor: 7.217
Authors: Geoffrey A Preidis; Mignon A Keaton; Philippe M Campeau; Brooke C Bessard; Margaret E Conner; Peter J Hotez Journal: J Nutr Date: 2013-12-31 Impact factor: 4.798
Authors: Gerald W Tannock; Corinda Taylor; Blair Lawley; Diane Loach; Maree Gould; Amy C Dunn; Alexander D McLellan; Michael A Black; Les McNoe; James Dekker; Pramod Gopal; Michael A Collett Journal: Appl Environ Microbiol Date: 2014-02-28 Impact factor: 4.792